USFDA issues EIR to unit-1 of Shilpa Medicare’s arm

15 May 2025 Evaluate

The United States Food and Drugs Administration (USFDA) has issued Establishment Inspection Report (EIR) to Shilpa Medicare’s 100% subsidiary -- Shilpa Pharma Lifesciences’ Unit-1 and the site is classified as Voluntary Action Indicated (VAI). The inspection was carried out at unit-1 by USFDA between March 3 to March 7, 2025.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

320.35 0.50 (0.16%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×